Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 December 2019 | Story Dr Cindé Greyling | Photo Supplied
When academics and economics meet

KovsieInnovation at the UFS is bridging the gap between industry and academics with a powerful force. For too long, research remained an academic pursuit, with many innovative ideas stuck between the pages of a thesis – only to come alive during exclusive, short-lived conference proceeds.


KovsieInnovation

Recently, Gerard Verhoef, Director in the Directorate: Research Development (DRD), and his team from KovsieInnovation finalised their Innovation and Commercialisation Strategy in order to create a structured pathway for good ideas. The primary objective of KovsieInnovation – the UFS Innovation and Entrepreneurship Office – is to achieve sustainable growth in third-stream income from innovative research activities stemming from the UFS. “Potential successful ideas must be feasible, viable, and sustainable, and we formulated an eight-step plan to facilitate this,” Verhoef explains. Ultimately, the DRD wants to attract new and continuous research as a renowned academic knowledge partner that can foster, drive, and successfully commercialise innovative research activities; and in doing so, foster an entrepreneurial culture at the UFS.


Liquid Culture

One such success story is the development of Liquid Culture into a business of choice, supplying liquid yeast to breweries and bakeries. Christopher Rothmann and Dr Errol Cason are the driving forces behind this company that produces their sought-after and stable yeast product in the Department of Microbiology, Biochemistry and Food Biotechnology at the UFS. With world-class equipment and laboratories, they house one of the largest yeast-culture collections in the world.

Both Rothman and Dr Cason were home brewers for many years before starting to produce commercial batches. They believe it would not have been possible without the help of KovsieInnovation. This project was also one of the finalists in the National Entrepreneurship Intervarsity.


Christo Strydom Nutrition (CSN)

Another innovative way in which the UFS generates third-stream income via the DRD, is by partnering with already successful commercial products. One such example is the recent successful royalty agreement with CSN. With this transaction, the university unlocked its brand potential to the benefit of both the industry partner and the UFS. Quality assurance remains the key success factor for deals like this.

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept